Dr. Simons worked as a specialist in surgery and holds an MBA from the University of Stellenbosch. In addition to his relevant experience as a specialist in the Düsseldorf University Hospital, Dr. Simons brings decades of international management experience to the company. Among other things, he was managing director of Ivy Sports Medicine GmbH and set up a branch in South Africa for the German endoscopy specialist Karl Storz.
dr Simons: “Regenerative procedures in medicine, especially in surgical orthopedics, are playing an increasingly important role. The demographic development and sporting activities of people up to old age present the treating physicians with completely new challenges. A few years ago, extensive cartilage damage in a joint meant pain for the patient, an increasingly severe restriction of activities and ultimately a joint replacement. CO.DON AG is countering this with innovative therapies, products and solutions, and I am very pleased to be taking the next strategic steps in corporate development together with Mr. Bur and the entire team.”
The company will be jointly managed by Dr. Achim Simons and Mr Tilmann Bur. Dr. In particular, Simons will be responsible for the European markets outside the DACH region as well as for business development as well as finance and scientific liaison. Mr. Bur will continue to be responsible for the markets in Germany, Austria and Switzerland (DACH), production, marketing, as well as the areas of human resources and law.
The expansion of the Management Board is intended to strengthen CO.DON AG, particularly in the European marketing of its approved drug and in the development of the product portfolio. Tilmann Bur, CEO of CO.DON AG: "On behalf of CO.DON AG, I would like to thank the Supervisory Board for the complementary reinforcement of the Management Board. Together we will advance the company's development and further expand our range of services in the interests of patients."
CO.DON AG develops, produces and sells endogenous cell therapies for the minimally invasive repair of cartilage defects. The drug offered is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint using only the body's own cartilage cells. The method offered by CO.DON is currently used in over 200 clinics in Germany and has already been used in over 15.000 patients. CO.DON received EU-wide approval for this drug in July 2017, and approval for Switzerland in March 2019. At the Leipzig site, CO.DON built one of the largest plants for the production of human cells on an industrial scale for in-house and contract production. The shares of CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Board of Directors of the company: Tilmann Bur.
For more information, please visit www.codon.de.
In December 2020, BIO Deutschland published its annual review.
c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully continued its growth in 2020 in an overall challenging year.